- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
ARVO Foundation for Eye Research celebrates 10th anniversary
Celebrating its 10th anniversary, the ARVO AFER provides ongoing support for a broad array of educational initiatives designed to enhance the conduct and dissemination of eye research.
Investment seminar
Through a 1-day seminar, "Unmet Needs: Emerging Frontiers in Ophthalmic Science," leading researchers and commercial experts will focus on promising ocular surface disorders and retinal diseases. The seminar, aimed at potential investors, will take place April 29, at the Hilton Marina Hotel, Fort Lauderdale, FL.
Speakers include:
In addition, Scott Pancoast, chief executive officer of Lpath Inc., a therapeutic antibody company, will share insights about Lpath's new retinal program partnership with Pfizer that was signed in December 2010.
The program will also feature ample networking opportunities through time set aside for individual meetings with companies and investors, as well as lunch and cocktails.
For program and registration information, go to http://www.arvofoundation.org/investors/.
